Nilsine Partners, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Nilsine Partners, LLC
- $912 Billion
- Q1 2025
A detailed history of Nilsine Partners, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Nilsine Partners, LLC holds 55,249 shares of CPRX stock, worth $1.38 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
55,249
Previous 33,519
64.83%
Holding current value
$1.38 Million
Previous $700 Million
91.52%
% of portfolio
0.15%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
388Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$467 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$212 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$138 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$85.4 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$78.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.57B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...